NEW YORK (GenomeWeb News) – RNAi services firm Cenix BioScience said today that it has extended an existing collaboration with CellCentric to validate epigenetic oncology drug candidates.
 
The new project follows a pilot study that the companies began in March under which Cenix used its RNAi-based phenotypic characterization platform to study several of CellCentric’s drug target candidates in a diverse panel of human cell lines.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.